Twist Bioscience (TWST) Net Equity Issued and Repurchased (2017 - 2020)

Twist Bioscience (TWST) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $323.9 million the latest figure, recorded in Q4 2020.

• In Q4 2020, Net Equity Issued and Repurchased rose 574.79% year-over-year to $323.9 million; the TTM figure through Jun 2023 stood at $323.9 million (down 32.42% YoY), while the FY2023 annual figure was $1.3 billion, changed 0.0% from the prior year.
• Net Equity Issued and Repurchased advanced to $323.9 million in Q4 2020 per TWST's latest filing, from $107.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $323.9 million in Q4 2020 and bottomed at $3.0 million in Q4 2017.
• Historically, Net Equity Issued and Repurchased has averaged $81.4 million across 4 years, with a median of $48.0 million in 2019.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 574.79% in 2020 and fell as far as 574.79% in 2020.
• Twist Bioscience's Net Equity Issued and Repurchased stood at $3.0 million in 2017, then soared by 133.34% to $7.0 million in 2018, then surged by 587.97% to $48.0 million in 2019, then surged by 574.79% to $323.9 million in 2020.
• Business Quant data shows TWST's Net Equity Issued and Repurchased at $323.9 million in Q4 2020, $107.4 million in Q2 2020, and $48.0 million in Q4 2019.